Soliris® (Eculizumab) is a monoclonal antibody in the category of immunosuppressive drugs used for the treatment of hemolytic blood disorders. SOLIRIS® works by selectively slowing down the complement system in the human body.
Soliris® is manufactured by Alexion.
Administration and Dosage:
Recommended administration of SOLIRIS® is an intravenous infusion weekly for 4 weeks following by the 5th dose 1 week later and then every 2 weeks thereafter.
Common Side Effects:
The more common side effects of SOLIRIS® include serious allergic reactions.
Please read the full Prescribing Information for SOLIRIS® and discuss any questions you have with your doctor.
Ready to Schedule an Appointment?
Please CLICK HERE to get started.
Soliris® is indicated to treat:
- Paroxysmal Nocturnal Hemoglobinuria
- Atypical Hemolytic Uremic Syndrome
- Generalized Myasthenia Gravis
- Neuromyelitis Optica Spectrum Disorder